Turgay Ulaş

405 total citations
58 papers, 235 citations indexed

About

Turgay Ulaş is a scholar working on Surgery, Hematology and Pathology and Forensic Medicine. According to data from OpenAlex, Turgay Ulaş has authored 58 papers receiving a total of 235 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Surgery, 17 papers in Hematology and 12 papers in Pathology and Forensic Medicine. Recurrent topics in Turgay Ulaş's work include Multiple Myeloma Research and Treatments (7 papers), Peptidase Inhibition and Analysis (5 papers) and Hematopoietic Stem Cell Transplantation (5 papers). Turgay Ulaş is often cited by papers focused on Multiple Myeloma Research and Treatments (7 papers), Peptidase Inhibition and Analysis (5 papers) and Hematopoietic Stem Cell Transplantation (5 papers). Turgay Ulaş collaborates with scholars based in Türkiye, Cyprus and Cambodia. Turgay Ulaş's co-authors include Mehmet Sinan Dal, Fevzi Altuntaş, Mehmet Ali Erkurt, Tuğçe Nur Yiğenoğlu, Tuba Hacıbekiroğlu, Serdal Korkmaz, Abdulkadir Baştürk, Yavuz Yeşilova, Taner Baştürk and İlhami Berber and has published in prestigious journals such as SHILAP Revista de lepidopterología, Bone Marrow Transplantation and Leukemia Research.

In The Last Decade

Turgay Ulaş

46 papers receiving 230 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Turgay Ulaş Türkiye 9 40 39 36 32 32 58 235
Aurélien Philippe France 10 31 0.8× 34 0.9× 38 1.1× 48 1.5× 23 0.7× 28 205
A. Laíz Spain 10 49 1.2× 34 0.9× 21 0.6× 27 0.8× 21 0.7× 45 272
Mehmet Akif Özdemir Türkiye 10 78 1.9× 29 0.7× 18 0.5× 29 0.9× 30 0.9× 34 272
Christophe Bovy Belgium 10 86 2.1× 46 1.2× 43 1.2× 35 1.1× 19 0.6× 29 275
Hyoungyoung Kim South Korea 11 33 0.8× 50 1.3× 11 0.3× 35 1.1× 33 1.0× 39 368
Antonio G. Tristano Venezuela 11 73 1.8× 78 2.0× 28 0.8× 30 0.9× 25 0.8× 25 454
Maria Comasia Leone Italy 11 17 0.4× 80 2.1× 14 0.4× 34 1.1× 27 0.8× 18 329
Ernie Yap United States 8 76 1.9× 22 0.6× 10 0.3× 26 0.8× 23 0.7× 33 203
Gürses Şahin Türkiye 12 49 1.2× 97 2.5× 30 0.8× 87 2.7× 69 2.2× 45 372
Almudena López‐Sampalo Spain 12 26 0.7× 31 0.8× 23 0.6× 53 1.7× 18 0.6× 29 360

Countries citing papers authored by Turgay Ulaş

Since Specialization
Citations

This map shows the geographic impact of Turgay Ulaş's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Turgay Ulaş with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Turgay Ulaş more than expected).

Fields of papers citing papers by Turgay Ulaş

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Turgay Ulaş. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Turgay Ulaş. The network helps show where Turgay Ulaş may publish in the future.

Co-authorship network of co-authors of Turgay Ulaş

This figure shows the co-authorship network connecting the top 25 collaborators of Turgay Ulaş. A scholar is included among the top collaborators of Turgay Ulaş based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Turgay Ulaş. Turgay Ulaş is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ulaş, Turgay, et al.. (2025). Challenges, Difficulties, and Delayed Diagnosis of Multiple Myeloma. Diagnostics. 15(13). 1708–1708.
2.
Toptaş, Tayfur, Mehmet Sinan Dal, Tuğçe Nur Yiğenoğlu, et al.. (2025). Anti-T lymphocyte globulin plus posttransplant cyclophosphamide 25 mg/kg versus posttransplant cyclophosphamide 50 mg/kg in patients with acute leukemias. Bone Marrow Transplantation. 60(6). 864–872. 1 indexed citations
3.
Hatipoğlu, Umur, et al.. (2025). Solitary Plasmacytomas: Current Status in 2025. Hematology Reports. 17(4). 32–32.
4.
Erkurt, Mehmet Ali, Si̇nan Demi̇rci̇oğlu, İlhami Berber, et al.. (2025). The role of heparin in autologous stem cell mobilization in patients with multiple myeloma. Transfusion and Apheresis Science. 64(4). 104185–104185.
5.
Yiğenoğlu, Tuğçe Nur, Mehmet Ali Erkurt, Simten Dağdaş, et al.. (2024). What is the role of alpha-1 antitrypsin in the management of acute graft versus host disease?. Transfusion and Apheresis Science. 64(1). 104057–104057.
6.
Yiğenoğlu, Tuğçe Nur, Sinem Namdaroğlu, Mehmet Ali Erkurt, et al.. (2024). Is there a relationship between vitamin D levels and graft versus host disease?. Transfusion and Apheresis Science. 64(1). 104054–104054.
7.
Ulaş, Turgay, et al.. (2023). Can orbital artery resistive indexes detect complications of diabetes in the prediabetic phase?. Wiener klinische Wochenschrift. 135(13-14). 343–348. 1 indexed citations
8.
Doğu, Mehmet Hilmi, Abdulkadir Baştürk, Si̇nan Demi̇rci̇oğlu, et al.. (2023). A Real-Life Turkish Experience of Ruxolitinib in Polycythemia Vera. SHILAP Revista de lepidopterología. 24(2). 120–125.
9.
Dal, Mehmet Sinan, Tuğçe Nur Yiğenoğlu, Semih Başçı, et al.. (2023). Real-world data on the effectiveness and safety of Ixazomib-Lenalidomide-Dexamethasone therapy in relapsed/refractory multiple myeloma patients: a multicenter experience in Turkey. Journal of Chemotherapy. 35(6). 563–569. 2 indexed citations
10.
Ulaş, Turgay, et al.. (2022). Highlighting steroid indications for Kikuchi Fujimoto disease: a case report. Çukurova medical journal (Online)/Çukurova medical journal. 47(4). 1753–1755.
11.
Dal, Mehmet Sinan, Olga Meltem Akay, Özgür Mehtap, et al.. (2021). Brentuximab vedotin and bendamustine: an effective salvage therapy for relapsed or refractory Hodgkin lymphoma patients. Journal of Chemotherapy. 34(3). 190–198. 8 indexed citations
12.
Dal, Mehmet Sinan, Mehmet Ali Erkurt, İrfan Kuku, et al.. (2021). Extracorporeal photopheresis in steroid-refractory chronic graft-versus-host disease: A retrospective multicenter study. Transfusion and Apheresis Science. 60(5). 103243–103243. 3 indexed citations
13.
Ulaş, Turgay, et al.. (2020). Publishing in Hematology Journals: A Scientometric and Economic Evaluation. Cureus. 12(12). e12069–e12069. 3 indexed citations
14.
Ulaş, Turgay, et al.. (2018). Kaposi sarcoma following autoimmune hemolytic anemia in a patient with chronic lymphocytic leukemia. memo - Magazine of European Medical Oncology. 12(1). 99–102. 1 indexed citations
15.
Boyacı, Nurefşan, et al.. (2015). Urothelial Carcinoma Concomitant With Malakoplakia In Non-Functioning Nephrolithic Kidneys. Folia Medica. 57(1). 78–79. 1 indexed citations
16.
Ulaş, Turgay, et al.. (2014). Does moxifloxacin alter oxidant status in the cornea? An experimental study. Cutaneous and Ocular Toxicology. 34(2). 139–143. 9 indexed citations
17.
Ulaş, Turgay, et al.. (2012). Levosimendan ve dobutamin tedavilerinin akut dekompanse kalp yetersizlikli hastalarda QT dispersiyonu üzerine etkisi: Prospektif bir çalışma. 12(1). 16–22. 1 indexed citations
18.
Ulaş, Turgay, et al.. (2012). The effect of levosimendan and dobutamine treatment on QT dispersion in patients with decompensated heart failure: a prospective study. Anadolu Kardiyoloji Dergisi/The Anatolian Journal of Cardiology. 12(1). 16–22. 3 indexed citations
19.
Ulaş, Turgay, et al.. (2012). Evaluation of ceruloplasmin levels in patients undergoing surgical interventions with nasal polyps. Auris Nasus Larynx. 40(3). 282–285. 5 indexed citations
20.
Ulaş, Turgay, et al.. (2011). Kararsız anjina pektoris ve ST-elevasyonsuz miyokart enfarktüslü hastalarda değişik statinlerin, ezetimib/simvastatin kombinasyonunun hsCRP düzeyleri üzerine etkileri: Randomize bir çalışma. 11(8). 703–710. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Aurélien Philippe Breakdown of academic impact, for papers by A. Laíz Breakdown of academic impact, for papers by Mehmet Akif Özdemir Breakdown of academic impact, for papers by Christophe Bovy Breakdown of academic impact, for papers by Hyoungyoung Kim Breakdown of academic impact, for papers by Antonio G. Tristano Breakdown of academic impact, for papers by Maria Comasia Leone Breakdown of academic impact, for papers by Ernie Yap Breakdown of academic impact, for papers by Gürses Şahin Breakdown of academic impact, for papers by Almudena López‐Sampalo
Rankless by CCL
2026